Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma

How targeted therapies and immunotherapies shape tumours and thereby influence subsequent therapeutic responses is poorly understood. Here, we show in melanoma patients and mouse models that when tumours relapse following targeted therapy with MAPK pathway inhibitors, they are cross-resistant to imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Haas, Lisa, Elewaut, Anais, Gerard, Camille L., Umkehrer, Christian, Leiendecker, Lukas, Pedersen, Malin, Krecioch, Izabela, Hoffmann, David, Novatchkova, Maria, Kuttke, Mario, Neumann, Tobias, de Silva, Ines Pires, Witthock, Harriet, Cuendet, Michel A., Carotta, Sebastian, Harrington, Kevin J., Zuber, Johannes, Scolyer, Richard A., Long, Georgina V., Wilmott, James S., Michielin, Olivier, Vanharanta, Sakari, Wiesner, Thomas, Obenauf, Anna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613740/
https://www.ncbi.nlm.nih.gov/pubmed/35121945
http://dx.doi.org/10.1038/s43018-021-00221-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613740/
https://www.ncbi.nlm.nih.gov/pubmed/35121945
http://dx.doi.org/10.1038/s43018-021-00221-9

Ejemplares similares